Processa Pharmaceuticals Inc (NAS:PCSA)
$ 1.19 -0.12 (-9.16%) Market Cap: 3.88 Mil Enterprise Value: -1.58 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 30/100

Processa Pharmaceuticals Inc at EBD Group Biotech Showcase Transcript

Jan 09, 2024 / 12:00AM GMT
Release Date Price: $6.23 (-3.91%)
Unidentified Participant

Hello. The next presenting company is Processa Pharmaceuticals, Inc. from Hanover, Maryland, USA. Processa Pharmaceuticals is focused on oncology. Presenting for Processa Pharmaceuticals is their CEO, George Ng. (Conference Instructions) Over to you, George.

George Ng
Processa Pharmaceuticals Inc - Chief Executive Officer, Director

Thank you very much. Thank you for attending our presentation this afternoon. My name is George Ng, and I'm the CEO of Processa Pharmaceuticals. We already are a pharmaceutical company that's developing next-generation chemotherapy drug. Before we begin, I just wanted to point out our forward-looking statement and disclosures. We may be making forward-looking statements as part of this presentation.

In terms of Processa Pharmaceuticals, as I mentioned previously, we are a company that's developing next-generation chemotherapy drug products. And we're in a unique position in that because we're doing that, that we're taking a de-risked strategy in the chemotherapy human regimens are known and used.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot